AUTOLOGOUS ENDOTHELIAL PROGENITOR CELLS (PROGENITOR CELLS THAT HAVE THE CAPACITY TO MIGRATE TO THE PERIPHERAL CIRCULATION AND TO DIFFERENTIATE INTO MATURE ENDOTHELIAL CELLS)
Liver Cirrhosis
Clinica Universidad de Navarra, Universidad de NavarraCell therapyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
143 Active assets in the Liver Cirrhosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PARITAPREVIR AbbVie | Phase 3 | A |
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) General Hospital of Shenyang Military Region | Phase 4 | BBB |
Tolvaptan Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Ribavirin Peking University People's Hospital | Phase 4 | BBB |
NORMAL HUMAN SERUM ALBUMIN King George's Medical University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
AUTOLOGOUS ENDOTHELIAL PROGENITOR CELLS (PROGENITOR CELLS THAT HAVE THE CAPACITY TO MIGRATE TO THE PERIPHERAL CIRCULATION AND TO DIFFERENTIATE INTO MATURE ENDOTHELIAL CELLS) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →